Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
NCT04522804Phase 1Completed
- Sponsor
- University of Utah
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by University of Utah. Primary endpoints: Number of adverse events (AEs) and serious adverse events (SAEs) at 8 months, Recruitment of patients with cancer diagnosis or hematologic malignancy at 18 months and 2 more. Started Oct 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04522804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522804.